BackBeat CNT treated patients experienced a mean reduction of 17.5 mmHg in office systolic blood pressure measured 24-months following therapy activation.

Excerpt from:
Orchestra BioMed™ Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant...

REDWOOD CITY, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the Centers for Medicare & Medicaid Services (“CMS”) will continue to provide increased Medicare reimbursement in the 340B outpatient hospital setting through year-end 2022 for 28 drugs, biologics and devices impacted by the COVID-19 public health emergency, including UDENYCA® (pegfilgrastim-cbqv).

Read the original here:
Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022

MIAMI, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the selection of Biorasi LLC (“Biorasi”) as its clinical research organization (CRO) to help conduct its Phase 2 clinical trial evaluating Lomecel-B infusion in Alzheimer’s Disease (AD) subjects.

The rest is here:
Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial

Bagsværd, Denmark, 5 November 2021 – Results from the STEP 5 phase 3b trial, presented today at the ObesityWeek® 2021 interactive congress, showed that adults treated with Wegovy™ (semaglutide 2.4 mg injection) achieved significant and sustained weight loss over the two-year study period. The STEP 5 trial investigated Wegovy™ vs. placebo, both used with a reduced calorie meal plan and increased physical activity for the treatment of obesity (BMI ?30 kg/m2) or overweight (BMI ?27 kg/ m2) in 304 adults with at least one weight-related comorbidity for 104 weeks (two years).1

View original post here:
Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity

Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed Study Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed Study

Read more:
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes

MONTREAL, Nov. 05, 2021 (GLOBE NEWSWIRE) -- I-MED Pharma USA is bringing the world’s most innovative dry eye product portfolio to the U.S. market. Their uniquely formulated line of ocular surface disorder products gives dry eye patients the long-lasting relief they have been searching for. I-MED Pharma USA will sell directly to eye care professionals throughout the United States, offering a broad range product portfolio which includes I-DROP® artificial tears, I-LID ’N LASH® ocular hygiene cleansers, I-DEFENCE® night-time dry eye ointment, I-VU® OMEGA-3 nutritional supplements, I-RELIEF™ therapeutic mask, and the E>Eye IRPL® device specifically designed to treat evaporative dry eye due to meibomian gland dysfunction.

More:
I-MED Pharma Set to Launch Its Innovative Dry Eye Product Portfolio in the U.S.A.

Sandusky, OH, Nov. 05, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today announced plans to add multiple new pharmaceutical products to its development pipeline in addition to its ongoing development of its RespRx CBD pharmaceutical for the treatment of Chronic Obstructive Pulmonary Disease (COPD).

Read this article:
PAOG Announces Plans To Add New Pharmaceutical Product Developments

BERKELEY, Calif. and MAINZ, Germany, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (Nasdaq:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the early detection of cancer, announces that its shares have commenced trading today on the Nasdaq Capital Market under the ticker symbol “MYNZ”.

Read this article:
MYNZ Shares Have Commenced Trading on the Nasdaq Capital Market

COPENHAGEN, Denmark – November 5, 2021 - Bavarian Nordic A/S (OMX:  BAVA) will announce its 2021 third quarter results on Friday, November 12, 2021.

View original post here:
Bavarian Nordic to Host Third Quarter 2021 Results Conference Call

NEW YORK, NY, Nov. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, has today reported continued strength and accelerating growth in its highest margin E-Commerce business segment (“E-Comm”).  The Company generated strong monthly E-Comm sales for the recently completed month of October 2021.  As of today’s date, November 5, 2021, the Company is firmly on track to generate record quarterly E-Comm sales – for its current operating quarter (October 1st– December 31st 2021).

Link:
Tauriga Sciences, Inc. Reports Continued Strength and Accelerating Growth in its Highest Margin E-Commerce Business Segment

Monthly information related to total number of voting rights and shares composing the share capital – October 30, 2021.

The rest is here:
Monthly information related to total number of voting rights and shares composing the share capital – October 30, 2021

Eyenovia will release third quarter 2021 results on Wednesday, November 10, after the close. The prior version of this press release incorrectly stated that third quarter 2021 results would be released on Thursday, November 11, after the close.

Originally posted here:
CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10

Company conference call and webcast at 4:30 PM ET Company conference call and webcast at 4:30 PM ET

Read more:
TFF Pharmaceuticals to Hold Third Quarter 2021 Financial and Business Results Conference Call on November 15, 2021

BERKELEY, Calif. and MAINZ, Germany, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the early detection of cancer, today announced that its common stock commenced trading on the Nasdaq Capital Market today under the ticker symbol MYNZ. The shares closed above the offering price at $9.99.

Go here to read the rest:
MYNZ Closes Its First Day of Trading on the Nasdaq Capital Market

NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in the following upcoming investor conferences in November:

View post:
atai Life Sciences to Participate in Upcoming November Investor Conferences

Bagsværd, Denmark, 5 November 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Follow this link:
Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2021

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Read the rest here:
Avicanna Announces Management Change

SAN DIEGO, Nov. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the California Competes Tax Credit Committee has approved the California Competes Tax Credit Allocation Agreement (the “Agreement”) between Sorrento and the California Governor’s Office of Business and Economic Development (“GO-Biz”). Pursuant to the Agreement, Sorrento has been awarded, subject to the satisfaction of certain milestones specified in the Agreement, an income tax credit from the State of California in an aggregate amount of up to $25,000,000. This incentivized credit is expected to support Sorrento’s vision of growth and expansion within the State of California.

Read the original:
Sorrento Awarded California Competes Tax Credit

HONG KONG, Shanghai and FLORHAM PARK, N.J., Nov. 07, 2021 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of HMPL-523 and HMPL-306 will be presented at the upcoming 63rd American Society for Hematology’s (ASH) Annual Meeting and Exposition, taking place on December 11-14, 2021. The meeting will be held virtually and in person at the Georgia World Congress Center in Atlanta, Georgia US.

Go here to read the rest:
HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting

Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders

Read this article:
CLINUVEL Expands Pharmaceutical Portfolio